Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-05-08
2007-05-08
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C544S277000, C536S027600, C536S027620, C514S263400
Reexamination Certificate
active
10263379
ABSTRACT:
The invention provides compounds having the following general formula (I):wherein X, R1, R2, R7and Z are as described here.
REFERENCES:
patent: 3892777 (1975-07-01), Gruenman et al.
patent: 4012495 (1977-03-01), Schmeichen et al.
patent: 4193926 (1980-03-01), Schmiechen et al.
patent: 4242345 (1980-12-01), Brenner et al.
patent: 4665074 (1987-05-01), Amschler
patent: 4824660 (1989-04-01), Angello et al.
patent: 4879296 (1989-11-01), Daluge et al.
patent: 4938949 (1990-07-01), Borch et al.
patent: 4956345 (1990-09-01), Miyasaka et al.
patent: 4965271 (1990-10-01), Mandell et al.
patent: 4968697 (1990-11-01), Hutchison
patent: 5070877 (1991-12-01), Mohiuddin et al.
patent: 5096906 (1992-03-01), Mandell et al.
patent: 5124455 (1992-06-01), Lombardo et al.
patent: 5140015 (1992-08-01), Olsson et al.
patent: 5189027 (1993-02-01), Miyashita et al.
patent: 5272153 (1993-12-01), Mandell et al.
patent: 5278150 (1994-01-01), Olsson et al.
patent: 5298508 (1994-03-01), Jacobson et al.
patent: 5364862 (1994-11-01), Spada et al.
patent: 5561134 (1996-10-01), Spada et al.
patent: 5565462 (1996-10-01), Eitan et al.
patent: 5593975 (1997-01-01), Cristalli
patent: 5593976 (1997-01-01), Mongelli et al.
patent: 5665754 (1997-09-01), Feldman et al.
patent: 5668139 (1997-09-01), Belardinelli et al.
patent: 5696254 (1997-12-01), Mansour et al.
patent: 5731296 (1998-03-01), Sollevi
patent: 5756706 (1998-05-01), Mansour et al.
patent: 5776940 (1998-07-01), Daluge et al.
patent: 5854081 (1998-12-01), Linden et al.
patent: 5877180 (1999-03-01), Linden et al.
patent: 5932558 (1999-08-01), Cronstein et al.
patent: 5998386 (1999-12-01), Feldman
patent: 6004945 (1999-12-01), Fukunaga
patent: RE36494 (2000-01-01), Olsson et al.
patent: 6020321 (2000-02-01), Cronstein et al.
patent: 6020339 (2000-02-01), Perrier et al.
patent: 6034089 (2000-03-01), Han et al.
patent: 6060481 (2000-05-01), LaNoue et al.
patent: 6117878 (2000-09-01), Linden et al.
patent: 6232297 (2001-05-01), Linden et al.
patent: 6303619 (2001-10-01), Linden et al.
patent: 6322771 (2001-11-01), Linden et al.
patent: 6326359 (2001-12-01), Monaghan et al.
patent: 6332771 (2001-12-01), Adams et al.
patent: 6339072 (2002-01-01), Martin et al.
patent: 6350735 (2002-02-01), Monaghan
patent: 6387889 (2002-05-01), Endo et al.
patent: 6448235 (2002-09-01), Linden et al.
patent: 6514949 (2003-02-01), Linden et al.
patent: 6525032 (2003-02-01), Mantell et al.
patent: 6531457 (2003-03-01), Linden et al.
patent: 6545002 (2003-04-01), Linden et al.
patent: 6624158 (2003-09-01), Mantell et al.
patent: 6670334 (2003-12-01), Linden et al.
patent: 6936596 (2005-08-01), Konno et al.
patent: 2002/0032168 (2002-03-01), Mantrell et al.
patent: 2002/0058641 (2002-05-01), Mantell et al.
patent: 2003/0013675 (2003-01-01), Yeadon et al.
patent: 2005/0182018 (2005-08-01), Linden et al.
patent: 2005/0282831 (2005-12-01), Beauglehole et al.
patent: 2006/0040888 (2006-02-01), Rieger et al.
patent: 2006/0040889 (2006-02-01), Rieger et al.
patent: 2006/0100169 (2006-05-01), Rieger et al.
patent: 2006/0217343 (2006-09-01), Rieger et al.
patent: 0488336 (1992-06-01), None
patent: 0488336 (1992-06-01), None
patent: 488336 (1995-05-01), None
patent: 0700908 (1996-03-01), None
patent: 1194440 (2002-04-01), None
patent: 1150991 (2004-04-01), None
patent: 1150991 (2004-04-01), None
patent: WO-93/22328 (1993-11-01), None
patent: WO-93/22328 (1993-11-01), None
patent: WO-95/11681 (1995-05-01), None
patent: WO-96/02553 (1996-02-01), None
patent: WO-9604280 (1996-02-01), None
patent: WO-9847509 (1998-10-01), None
patent: WO-98/57651 (1998-12-01), None
patent: WO-98/57651 (1998-12-01), None
patent: WO-99/34804 (1999-07-01), None
patent: WO-99/38877 (1999-08-01), None
patent: WO-99/41267 (1999-08-01), None
patent: WO-99/62518 (1999-12-01), None
patent: WO-99/63938 (1999-12-01), None
patent: WO-99/67263 (1999-12-01), None
patent: WO-99/67264 (1999-12-01), None
patent: WO-99/67265 (1999-12-01), None
patent: WO-99/67266 (1999-12-01), None
patent: WO-00/44763 (2000-01-01), None
patent: WO-00/23457 (2000-04-01), None
patent: WO-00/72799 (2000-12-01), None
patent: WO-00/78774 (2000-12-01), None
patent: WO-00/78777 (2000-12-01), None
patent: WO-01/94368 (2001-12-01), None
patent: WO-02/09701 (2002-02-01), None
patent: WO-02/096462 (2002-12-01), None
patent: WO-03/014137 (2003-02-01), None
patent: WO-03/029264 (2003-04-01), None
patent: WO-03/086408 (2003-10-01), None
patent: WO-2005/097140 (2005-10-01), None
patent: WO-2006/015357 (2006-02-01), None
patent: WO-2006/023272 (2006-03-01), None
patent: WO-2006/028618 (2006-03-01), None
March, Advanced Organic Chemistry (4thdefition) Wiley, 1992, p. 400.
Buster, B, et al., “The Effect of Adenosine receptor agonists on neutrophil Pleocytosis and Blood-Brain Barrier -Pathophysiology in Experimental Bacterial Meningitis,”Program and Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy,Vo. 37, (1997), p. 39.
Camaioni, E, et al., “Adenosine receptor agonists: synthesis and bilogical evaluation of the diastereoisomers of 2-(3-Hydroxy-3-phenyl-1-propyn-1-yl) NECA,”Bioorganic&Medicinal Chemistry,5(12), (Dec. 1997), pp. 2267-2275.
Cassada, D C., et al., “Adenosine A2A agonist reduces paralysis after spinal cord ischemia: correlation with A2A receptor expression on motor neurons,”Annals of Thoracic Surgery,74(3), (Sep. 2002), pp. 846-849; discussion pp. 849-850.
Cassada, D C., et al., “Adenosine A2A analogue ATL-146e reduces systemic tumor necrosing factor and spinal cord capillary platelet-endothelial cell adhesion molecule-1 expression after spinal cord ischemia,”Journal of Vascular Surgery,35(5), (May 2002), pp. 994-998.
Cassada, D C., et al., “Adenosine A2A analogue improves neurologic outcome after spinal cord trauma in the rabbit.,”Journal of Trauma-Injury Infection&Critical Care,53(2), (Aug. 2002), pp. 225-229.
Cassada, D C., et al., “Adenosine analogue reduces spinal cord reprefusion injury in a time-dependent fashion,”Surgery,130(2), (Aug. 2001), pp. 230-235.
Cassada, D C., et al., “An adenosine A2A agonist, ATL-146e, reduces paralysis and apoptosis during rabbit spinal cord reperfusion.,”Journal of Vascular Surgery,34(3), (Sep. 2001), pp. 482-488.
Cassada, D C., et al., “Systemic adenosine A2 agonist ameliorates ischemic reperfusion injury in the rabbit spinal cord,”Annals of Thoracic Surgery,72(4), (Oct. 2001), pp. 1245-1250.
Cronstein, B N., et al., “Neutrophil Adherence to Endothelium is Enhanced Via Adenosine A1 Receptors and Inhibited Via Adenosine A2 Receptors,”The Journal of Immunology,148(7), (1992), pp. 2201-2206.
Day, Y J., “Protection from ischemic liver injury by activation of A2A adenosine receptors during reperfusion: inhibition of chemokine induction,”Am J Physiol Gastrointest Liver Physiol,286, (Feb. 2004), pp. G285-293.
Day, Y J., et al., “Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells.,”Journal of Clinical Investigation,112(6), (Sep. 2003),pp. 883-891.
De La Harpe, J., “Adenosine Regulates the Respiratory Burst Of Cytokine—Triggered Human Neutrophils Adherent To Biological Surfaces,”Journal of Immunology,143(2), (1989), pp. 596-602.
De Zwart, M, et al., “5-N-Substituted Carboxamidoadenosines as Agonists for Adenosine Receptors,”Journal of Medicinal Chemistry,42(8), (Apr. 22, 1999), pp. 1384-1392.
Dechatelet, L R., et al., “Mechanism of the Luminol-Dependent Chemiluminescence of Human Neutrophils,”The Journal of Immunology,129 (4), (1982), pp. 1589-1593.
Fenster, M. S., et al., “Activation of Adenosine A2a Receptors Inhibits Mast Cell Degranulation and Mast Cell-Dependent Vasoconstriction,”Microcirculation,7, (2000), pp. 129-135.
Fiser, S M., et al., “Adenosine A2A receptor activation decreases reperfusion injury associated with high-flow reperfusion.,”Journal of Thoracic&Cardiovascular Surgery,124(5), (Nov. 200
Figler Robert Alan
Linden Joel M.
Macdonald Timothy L.
Murphree Lauren Jean
Rieger Jayson M.
Berch Mark L.
Schwegman Lundberg Woessner & Kluth P.A.
University of Virginia Patent Foundation
LandOfFree
2-propynyl adenosine analogs having A 2A agonist activity... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2-propynyl adenosine analogs having A 2A agonist activity..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-propynyl adenosine analogs having A 2A agonist activity... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3773466